These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36285862)

  • 1. Diagnostic and therapeutic approach to pulmonary infiltrates in cancer patients receiving immune checkpoint inhibitors.
    Fernández-Ruiz M
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):67-73. PubMed ID: 36285862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs].
    Kamyshova ES; Bobkova IN; Sekacheva MI
    Ter Arkh; 2021 Jun; 93(6):649-660. PubMed ID: 36286830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
    Jo W; Won T; Daoud A; Čiháková D
    Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
    Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
    Front Immunol; 2022; 13():804597. PubMed ID: 35432346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
    Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical burden of immune checkpoint inhibitor-induced pneumonitis.
    Sakamoto K; Fukihara J; Morise M; Hashimoto N
    Respir Investig; 2020 Sep; 58(5):305-319. PubMed ID: 32713811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study.
    Ma KS; Chiang CH; Chen ST; Dinh Y; Chiang CH; Van Dyke TE; Sullivan R; Ananthakrishnan AN; Hsia YP; Peng CM; Chiang CH
    Cancer Lett; 2024 Aug; 598():217100. PubMed ID: 38969158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
    Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
    Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
    Wojtukiewicz MZ; Rek MM; Karpowicz K; Górska M; Polityńska B; Wojtukiewicz AM; Moniuszko M; Radziwon P; Tucker SC; Honn KV
    Cancer Metastasis Rev; 2021 Sep; 40(3):949-982. PubMed ID: 34236546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.